PrenatalSafe® is a non-invasive prenatal test that detects chromosomal abnormalities by analyzing cell-free fetal DNA from a pregnant woman’s blood sample. PrenatalSafe® Karyo Plus represents an evolution of the PrenatalSafe® Karyo test. In addition to the possibility of detecting aneuploidies and structural chromosomal abnormalities affecting each chromosome, with results very similar to the determination of the fetal karyotype performed with invasive prenatal diagnostic techniques, PrenatalSafe® Karyo Plus makes it possible to identify the presence in the fetus of submicroscopic structural chromosomal abnormalities, such as 9 of the most common microdeletion syndromes. This test also includes fetal sex determination (optional).
Microdeletion syndrome
Chromosomal Region
Prevalence (at birth)
DiGeorge Syndrome
22q11.2 deletion
1/2.000 – 1/4.000
Cri-du-chat Syndrome
5p15.3 deletion
1/15.000 – 1/50.000
Prader-Willi Syndrome
15q11.2 deletion
1/25.000
Angelman Syndrome
15q11.2 deletion
1/10.000 – 1/20.000
1p36 deletion Syndrome
1p36 deletion
1/5.000 – 1/10.000
Wolf-Hirschhorn Syndrome
4p16.3 deletion
1/20.000 -1/50.000
Jacobsen Syndrome
11q23-q24.3 deletion
1/100.000
Langer-Giedion Syndrome
8q24.11-q24.13 deletion
1/200.000
Smith-Magenis Syndrome
17p11.2 deletion
1/15.000 – 1/25.000
PrenatalSafe® Karyo Plus is not indicated for dichorionic twin pregnancies.
PrenatalSafe® Karyo Plus can be integrated, for free, with RhSafe® test, a non-invasive prenatal exam that, analyzing the fetal DNA isolated from a blood sample of the mother to be, allows to determine fetal Rh(D) Factor. RhSafe® test is optional, and is performed for free (on request) in Rh(D) negative pregnant women, with a Rh(D) positive male partner.
